G protein coupled receptor 30 (GPER1) Human shRNA Plasmid Kit (Locus ID 2852)
CAT#: TG316565
GPER1 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 4 publications. |
Product images
经常一起买 (2)
Specifications
Product Data | |
Product Name | G protein coupled receptor 30 (GPER1) Human shRNA Plasmid Kit (Locus ID 2852) |
Locus ID | 2852 |
UniProt ID | Q99527 |
Synonyms | FEG-1, LERGU, CMKRL2, LERGU2, GPCR-Br, MGC99678 |
Vector | pGFP-V-RS |
Format | Retroviral plasmids |
Kit Components | GPER1 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 2852). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free. |
RefSeq | NM_001031682, NM_001039966, NM_001098201, NM_001505, NM_001039966.1, NM_001098201.1, NM_001505.1, NM_001505.2, BC011634, BC011634.1, BC067849, BC082766, BM672716, NM_001505.3, NM_001098201.3 |
Summary | This gene encodes a multi-pass membrane protein that localizes to the endoplasmic reticulum and a member of the G-protein coupled receptor 1 family. This receptor binds estrogen and activates multiple downstream signaling pathways, leading to stimulation of adenylate cyclase and an increase in cyclic AMP levels, while also promoting intracellular calcium mobilization and synthesis of phosphatidylinositol 3,4,5-trisphosphate in the nucleus. This protein therefore plays a role in the rapid nongenomic signaling events widely observed following stimulation of cells and tissues with estrogen. This receptor has been shown to play a role in diverse biological processes, including bone and nervous system development, metabolism, cognition, male fertility and uterine function. [provided by RefSeq, Aug 2017] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (4)
The use of this RNAi has been cited in the following citations: |
---|
Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells
,Yang, F;Xie, H;Yang, L;Zhang, L;Zhang, F;Liu, H;Li, D;Shao, Z;,
Autophagy
[GPER1]
|
Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2.
,null,
Journal of cancer research and clinical oncology
,PubMed ID 22270964
[GPER1]
|
The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells.
,null,
Biochemical and biophysical research communications
,PubMed ID 22425989
[GPER1]
|
Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.
,null,
Cancer science
,PubMed ID 19432902
[GPER1]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...